TABLE 2.
Summary of F-derived peptides that are involved in CD4 memory T-cell responses in PBMC from healthy donorsa
| Peptide | No. of spots/106 PBMC
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CE-8 (DRB1*03, DQB1*02) | CE-4 (DRB1*01, DRB1*03, DQB1*05, DQB1*02) | CE-7 (DRB1*01, DQB1*05) | VB-6 (DRB1*0401, DRB4*01, DQB1*03) | MP-7 (DRB1*0401, DRB1*0407, DQB1*03) | VB-5 (DRB1*0401, DRB1*0403, DQB1*03) | CE-3 (DRB1*0401, DRB1*03, DQB1*03, DQB1*02) | MP-1 (DRB1*0401, DRB1*1301, DQB1*03, DQB1*06) | MP-4 (DRB1*1301, DQB1*06, DQB1*02) | VP-1 (DRB1*15, DRB1*1302, DQB1*06) | VB-2 (DRB1*1101, DRB1*0701, DQB1*03) | VB-7 (DRB1*1101, DRB1*15, DQB1*03, DQB1*06) | CH-1 (DRB1*16, DRB1*15, DQB1*0502, DQB1*0602) | JB-1 (DRB1*15, DRB1*09, DQB1*0602, DQB1*03) | |
| 2 | 4 | 13 | 46 DR | 21 | 103 | 94 DR | 9 | 47 | 10 | 6 | 0 | 15 | 13 | |
| 3 | 35 DR | 14 | 0 | 2 | 10 | NT | ||||||||
| 5 | 5 | 5 | 79 | 104 | 176 | 37 | 55 | 1 | −2 | 40 | −4 | 8 | ||
| 6 | 9 | 5 | −6 | 70 | 104 | 143 DR | 29 | 43 | 26 DR | −4 | 3 | |||
| 8 | 8 | 3 | 8 | 9 | 2 | −1 | 4 | 1 | 30 | −1 | ||||
| 9 | 0 | 8 | 2 | 45 | 15 | 2 | 22 | −1 | 11 | −5 | ||||
| 10 | −1 | 10 | 4 | 39 | 20 | 1 | 0 | 30 DR | −3 | 13 | −3 | |||
| 13 | 9 | 1 | 9 | 28 | 13 | 11 | 20 | −1 | 12 | 21 DR | 10 | 5 | ||
| 14 | 0 | 5 | 60 | 72 | 50 DR | 24 | 55 | 2 | 14 | 1 | 19 | 21 | ||
| 15 | 3 | 4 | 49 | 72 | 41 | 25 | 39 | 24 | 3 | 12 | ||||
| 19 | 3 | 1 | −1 | 35 | 5 | 16 | 2 | −7 | 5 | |||||
| 20 | 3 | 3 | −3 | −1 | 31 | 23 | 10 | 5 | 5 | |||||
| 30 | 9 | 2 | 0 | 9 | 12 | 0 | 0 | 48 DR | 5 | −1 | ||||
| 33 | 1 | 1 | 8 | 7 | 4 | 10 | 1 | 6 | 37 DR | 5 | 1 | |||
| 39 | −1 | 10 | −7 | −1 | 4 | 24 | 14 | 0 | 0 | 42 | 47 DR | −7 | ||
| 40 | 4 | 18 | 38 DR | −1 | 9 | 7 | 1 | −3 | 0 | 8 | −4 | |||
| 45 | 25 | 7 | 4 | −3 | 4 | 23 | 8 | −3 | 44 DQ | |||||
| 46 | 13 | 9 | −4 | 6 | 30 | 2 | 10 | 8 | 68 DQ | |||||
| 50 | 5 | 1 | 68 DQ | −3 | 11 | 37 DR | 3 | 4 | 23 DQ | 76 DQ | 4 | −4 | ||
| 51 | 3 | 3 | 57 DQ | 3 | 21 | 73 DR | 4 | 41 | 22 DQ | 70 DQ | −1 | 0 | ||
| 57 | 44 | 18 | −3 | 11 | 37 | 13 | 43 | 51 | 4 | 58 DR | 103 DR | −4 | ||
| 58 | 7 | 2 | −5 | 15 | 25 | 0 | 10 | 20 | 13 | −7 | −1 | |||
| 66 | 3 | 2 | 23 | 79 | 105 DR | 31 | 2 | −3 | 8 | |||||
| 69 | −4 | −5 | 4 | 32 DR | 15 | 28 DR | 23 | |||||||
| 72 | 4 | −1 | 17 | 63 | 85 DR | 25 | 0 | −5 | 1 | |||||
| 77 | 3 | 11 | 40 DR | −3 | 13 | 2 | 1 | −5 | 23 | 5 | ||||
| 79 | 4 | 10 | −1 | 5 | −3 | 14 | 5 | 44 DR | 12 | |||||
| 83 | 3 | −3 | 21 | 0 | 4 | 7 | −7 | |||||||
| 84 | 9 | 2 | 23 | 24 | 10 | 3 | 4 | −7 | ||||||
| 87 | 15 | −3 | 3 | 7 | 28 | 5 | ||||||||
| 91 | 11 | −3 | 1 | 0 | −3 | 44 DR | −4 | 1 | 15 | |||||
a
Individual peptides were tested in a direct 24-h Elispot assay (triplicate) with PBMC of healthy blood donors. Numbers of spots per 106 PBMC are depicted. Peptides found positive in more than one experiment are boldfaced. For donors CE-3, 4, and 7, MP-1 and 7, VP-1, VB-2, and CH-1, only single peptides of positive pools were tested. When antibody blocking was performed to distinguish between HLA-DR and -DQ responses, this is indicated. NT, not tested.